C1 inhibitor: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: C1INH ==Adult Dosing== ===Angioedema<ref>Craig TJ, Levy RJ, Wasserman RL, et al. Eff...") |
|||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Angioedema<ref>Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009; 124(4):801.</ref>=== | ===[[Angioedema]]<ref>Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009; 124(4):801.</ref>=== | ||
*1000 units if ≤50kg | *1000 units if ≤50kg | ||
*1500 units if >50-75kg | *1500 units if >50-75kg | ||
Revision as of 16:03, 17 August 2019
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names: C1INH
Adult Dosing
Angioedema[1]
- 1000 units if ≤50kg
- 1500 units if >50-75kg
- 2000 units if >75-100kg
- 2500 units if >100kg
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
See Also
References
- ↑ Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009; 124(4):801.